BACKGROUND OF THE INVENTION
The present invention is concerned with novel quinoline derivatives useful as neuropeptide Y (NPY) receptor ligands, particularly neuropeptide Y (NPY) antagonists, and even more particularly selective neuropeptides Y Y5 receptor antagonists. Accordingly, the compounds of
BACKGROUND OF THE INVENTION
The present invention is concerned with novel quinoline derivatives useful as neuropeptide Y (NPY) receptor ligands, particularly neuropeptide Y (NPY) antagonists, and even more particularly selective neuropeptides Y Y5 receptor antagonists. Accordingly, the compounds of
BACKGROUND OF THE INVENTION
The present invention is concerned with novel quinoline derivatives useful as neuropeptide Y (NPY) receptor ligands, particularly neuropeptide Y (NPY) antagonists, and even more particularly selective neuropeptides Y Y5 receptor antagonists. Accordingly, the compounds of
BACKGROUND OF THE INVENTION
The present invention is concerned with novel quinoline derivatives useful as neuropeptide Y (NPY) receptor ligands, particularly neuropeptide Y (NPY) antagonists, and even more particularly selective neuropeptides Y Y5 receptor antagonists. Accordingly, the compounds of
BACKGROUND OF THE INVENTION
Neuropetide Y is a 36 amino acid peptide that is widely distributed in the central and peripheral nervous systems. This peptide mediates a number of physiological effects through its various receptor subtypes. Studies in animals have shown that neuropeptide Y is a
PRIORITY TO RELATED APPLICATION(S)
This application claims the benefit of PCT/CN2010/074931, filed Jul. 2, 2010, which is hereby incorporated by reference in its entirety.
FIELD OF THE INVENTION
The invention relates to compounds which are activators of AMP-activated protein kinase (AMPK) and which
BACKGROUND
Field
The present invention relates to certain disubstituted 1,5-naphthyridine and quinoline compounds as inhibitors of monamine oxidase, and monoamine oxidase B in particular; derivatives of such compounds; compositions of such compounds; methods of making them; and their use in various
BACKGROUND
1. Field
The present invention relates to certain disubstituted 1,5-naphthyridine and quinoline compounds as inhibitors of monamine oxidase, and monoamine oxidase B in particular; derivatives of such compounds; compositions of such compounds; methods of making them; and their use in
BACKGROUND
Field
The present invention relates to certain disubstituted 1,5-naphthyridine and quinoline compounds as inhibitors of monoamine oxidase, and monoamine oxidase B in particular; derivatives of such compounds; compositions of such compounds; methods of making them; and their use in various
BACKGROUND
1. Field
The present invention relates to certain disubstituted 1,5-naphthyridine and quinoline compounds as inhibitors of monamine oxidase, and monoamine oxidase B in particular; derivatives of such compounds; compositions of such compounds; methods of making them; and their use in
FIELD OF THE INVENTION
This invention relates to compounds that inhibit the secretion of apolipoprotein B, and to methods of treating and/or preventing atherosclerosis, obesity, diabetes, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia,
FIELD OF THE INVENTION
This invention relates to compounds that inhibit the secretion of apolipoprotein B, and to methods of treating and/or preventing atherosclerosis, obesity, diabetes, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia,
BACKGROUND
The neurotransmitter/hormone serotonin (5-hydroxytryptamine, 5-HT) regulates many physiological processes via a group of at least 14 distinct receptors that are organized into 7 subfamilies (Hoyer, D., et al., Pharmacol. Rev., 46, 1994). The 5-HT.sub.2 subfamily is composed of the
TECHNICAL FIELD
The present invention relates to a quinoline compound having a melanin-concentrating hormone (hereinafter sometimes to be abbreviated as MCH) antagonistic action and useful as an agent for preventing or treating obesity and the like.
BACKGROUND ART
Feeding behavior is an
FIELD OF THE INVENTION
The present invention relates to organic compounds useful for therapy or prophylaxis in a mammal, and in particular to fatty-acid binding protein (FABP) 4 and/or 5 inhibitors, more particularly dual FABP 4/5 inhibitors for the treatment or prophylaxis of lipodystrophy, type 2
The most complete medicinal herbs database backed by science
Works in 55 languages
Herbal cures backed by science
Herbs recognition by image
Interactive GPS map - tag herbs on location (coming soon)
Read scientific publications related to your search
Search medicinal herbs by their effects
Organize your interests and stay up do date with the news research, clinical trials and patents
Type a symptom or a disease and read about herbs that might help, type a herb and see diseases and symptoms it is used against. *All information is based on published scientific research